Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

udy enrolled prior to the fourth quarter of 2013.
  • Phase III study of ibrutinib versus chlorambucil in frontline newly diagnosed elderly CLL/SLL patients, RESONATE™ -2.  This trial is a randomized, multicenter, open-label study of ibrutinib as a monotherapy versus chlorambucil in patients 65 years or older with treatment naïve CLL/SLL. The study design was granted a Special Protocol Assessment (SPA), designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival when compared to chlorambucil. This global study is open and Pharmacyclics plans to enroll 272 patients worldwide. The Company anticipates enrollment for this study will take approximately 18 months to complete. 
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL, HELIOS (CLL3001). This trial is a randomized, multi-center, double blinded, placebo controlled trial of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to bendamustine and rituximab. This global study, conducted by Janssen, is open and Janssen plans to enroll 580 patients worldwide.
  • Phase II study, RESONATE™ -17p, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment with chemo immunotherapy (a high unmet need population). The primary endpoint of the study will be overall response rate. This global study is open and Pharmacyclics plans to enroll 111 patients worldwide. The Company anticipates enrollment for this study will take approximately 12 months to complete.
  • Phase III study of ibrutinib ver
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... zFlo Motion , a US leader in biomechanics software ... a new partner. STT-Systems has developed an impressive ... with offerings in the optical-motion capture, 3D scanning, and industrial ... unit), iSen, is opening eyes around the world. With no ...
    (Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
    (Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
    (Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
    Breaking Biology Technology:3D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
    ... The Midwest has been approached by a variety of ... between regional biotech communities. These groups include: , ,1. The ... ,6. The Singaporeans ,7. The Danish , ,None, however, have ... Japanese. , ,In at least two previous columns, you ...
    ... brought Bill Gates to his tender knees. Oh, yes, you could ... writer, you!" It echoed among the buildings, all but drowning out ... whimpers you could almost hear Billy saying it: "I will, I ... software."* , ,Wow, if only the U.S. antitrust lawyers ...
    ... growth rate, we wont have enough power in 15 years, ... With a 2.5 percent growth rate, if we dont build ... the lights on in 15 years, especially in this state, ... Wilson, Ph.D, assistant professor of engineering physics at the University ...
    Cached Biology Technology:Japanese Continue Relentless Biotech Stake in Midwest 2Japanese Continue Relentless Biotech Stake in Midwest 3Japanese Continue Relentless Biotech Stake in Midwest 4Japanese Continue Relentless Biotech Stake in Midwest 5Japanese Continue Relentless Biotech Stake in Midwest 6Japanese Continue Relentless Biotech Stake in Midwest 7Japanese Continue Relentless Biotech Stake in Midwest 8Japanese Continue Relentless Biotech Stake in Midwest 9Open Letter: Blasted Worm 2Open Letter: Blasted Worm 3Software Company Tackles Energy Shortage Issues 2
    (Date:12/17/2014)... fundamentally transforming the travel experience and nowhere is this ... decade, ePassports, biometric readers, and secure document scanners have ... via eGates and Automated Passport Control (APC) Kiosks at ... across the globe. According to ...
    (Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
    (Date:12/11/2014)...  That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ...
    Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
    ... of UC Davis scientists has shown in experimental mouse ... administration of three times the maximum tolerated dose of ... to more effective cancer control without increasing toxicity. ... home in on tumor cells while carrying the anti-cancer ...
    ... This press release is available in German ... Slovakia have pointed out that the chemical triclosan is ... status of rivers that are still not sufficiently monitored. ... that was more comprehensive than standard monitoring procedures, concentrations ...
    ... a global life sciences technology solutions company specializing in ... provider of clinical research services, are pleased to announce ... ™ Partner Program and will offer ... support the research initiatives of their pharmaceutical, biotechnology, and ...
    Cached Biology News:UC Davis researchers develop new drug delivery system for bladder cancer using nanoparticles 2UC Davis researchers develop new drug delivery system for bladder cancer using nanoparticles 3Triclosan needs to be monitored 2Advanced Clinical Joins MedNet Solutions' iMedNet Partner Program 2
    ... multicolor analysis in a modern flow cytometer, ... that are differentially labeled with fluorescent probes. ... typically used for cell labeling are broader ... a flow cytometers filters. Thus, the fluorescence ...
    ... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
    ... ActiveSight, the leading provider of ... design, offers fragment-based screening services to ... screening involves the binding of drug-like ... crystallized protein drug targets, allowing scientists ...
    ...
    Biology Products: